Details for Patent: 8,268,848

✉ Email this page to a colleague

Which drugs does patent 8,268,848 protect, and when does it expire?

Patent 8,268,848 protects DAYVIGO and is included in one NDA.

This patent has thirty-six patent family members in thirty-two countries.

Summary for Patent: 8,268,848

Scope and claims summary:

Title:	Cyclopropane compound
Abstract:	A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: ##STR00001## wherein Q represents --CH-- or a nitrogen atom, R.sub.1a and R.sub.1b each independently represent a C.sub.1-6 alkyl group and the like, R.sub.1c represents a hydrogen atom and the like, R.sub.2a, R.sub.2b, R.sub.2c and R.sub.2d each independently represent a hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group and the like, R.sub.3a, R.sub.3b and R.sub.3c each independently represent a hydrogen atom, a halogen atom and the like, and R.sub.3d represents a hydrogen atom and the like.
Inventor(s):	Terauchi; Taro (Tsukuba, JP), Takemura; Ayumi (Tsukuba, JP), Doko; Takashi (Tokyo, JP), Yoshida; Yu (Tsukuba, JP), Tanaka; Toshiaki (Tsukuba, JP), Sorimachi; Keiichi (Tsukuba, JP), Naoe; Yoshimitsu (Tsukuba, JP), Beuckmann; Carsten (Tsukuba, JP), Kazuta; Yuji (Tsukuba, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	13/237,205
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 8,268,848

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE	⤷ Subscribe
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,268,848

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2010-211629	Sep 22, 2010

International Family Members for US Patent 8,268,848

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	083060	⤷ Subscribe
Australia	2011304285	⤷ Subscribe
Brazil	112013006594	⤷ Subscribe
Canada	2811895	⤷ Subscribe
Chile	2013000784	⤷ Subscribe
China	103153963	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.